S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target

T. Y. Seiwert; A. J. Klein-Szanto; R. Jagadeeswaran; M. Tretiakova; L. Martin; M. W. Lingen; E. E. Cohen; J. A. Ridge; E. E. Vokes; R. Salgia

doi:10.1001/archotol.132.8.864-b

Oral Presentations: American Head and Neck Society

August 2006

S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target

T. Y. Seiwert; A. J. Klein-Szanto; R. Jagadeeswaran; et al M. Tretiakova; L. Martin; M. W. Lingen; E. E. Cohen; J. A. Ridge; E. E. Vokes; R. Salgia

Arch Otolaryngol Head Neck Surg. 2006;132(8):864. doi:10.1001/archotol.132.8.864-b

Full Text

University of Chicago, Chicago, Ill;

Fox Chase Cancer Center, Philadelphia, Pa

Objective: To determine mutations of the receptor tyrosine kinase c-MET in head and neck squamous cell carcinoma (HNSCC) and evaluate c-MET as a potential novel target using c-MET inhibitor SU11274.

Design: A total of 128 HNSCC, dysplastic, and normal tissues (using immunohistochemistry) and 7 HNSCC cell lines (using immunoblot) were evaluated for c-MET, phospho-c-MET, and hepatocyte growth factor.

Full Text

S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target

Others Also Liked

Featured Articles

USPSTF Recommendation Statements

Blogs

S115 The Receptor Tyrosine Kinase c-MET Is Mutated in Head and Neck Cancer and Is a Promising Novel Target

Read More About

Citation

Download citation file:

Others Also Liked

Select Your Interests